Abstract 16127: Effect of REGN727/SAR236553 Anti-Proprotein Convertase Subtilisin/Kexin Type 9 Fully Human Monoclonal Antibody in Patients with Elevated Triglycerides/Low High-Density Lipoprotein Cholesterol: Data from Three Phase 2 Studies (NCT:01266876; 01288469; 01288443)

Robert Dufour,Patrick M. Moriarty,Elisabeth Genestin,William J. Sasiela,Yunling Du,Anne-Catherine Ferrand,Henry N. Ginsberg

Abstract 16127: Effect of REGN727/SAR236553 Anti-Proprotein Convertase Subtilisin/Kexin Type 9 Fully Human Monoclonal Antibody in Patients with Elevated Triglycerides/Low High-Density Lipoprotein Cholesterol: Data from Three Phase 2 Studies (NCT:01266876; 01288469; 01288443)

2012

Robert Dufour
Patrick M. Moriarty
Elisabeth Genestin
William J. Sasiela
Yunling Du
Anne-Catherine Ferrand
Henry N. Ginsberg

Background: Low-density lipoprotein cholesterol (LDL-C) is regarded as the primary target for risk reduction in hypercholesterolemia. However, patients with associated high triglycerides (TGs) and ...

Keywords:

Kexin
Cardiology
Subtilisin
Low high-density lipoprotein cholesterol
Endocrinology
Proprotein convertase
Diabetes mellitus
Monoclonal antibody
Biochemistry
Internal medicine
Medicine
lipoprotein cholesterol
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations